

# Maria Martinez-Garcia

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/426631/publications.pdf>

Version: 2024-02-01

13  
papers

498  
citations

933264

10  
h-index

1125617

13  
g-index

13  
all docs

13  
docs citations

13  
times ranked

991  
citing authors

#	ARTICLE	IF	CITATIONS
1	SEOM-GEINO clinical guideline of systemic therapy and management of brain central nervous system metastases (2021). <i>Clinical and Translational Oncology</i> , 2022, 24, 703-711.	1.2	2
2	RNA sequencing and Immunohistochemistry Reveal ZFN7 as a Stronger Marker of Survival than Molecular Subtypes in G-CIMP <sup>+</sup> negative Glioblastoma. <i>Clinical Cancer Research</i> , 2021, 27, 645-655.	3.2	5
3	Vanucizumab mode of action: Serial biomarkers in plasma, tumor, and skin-wound-healing biopsies. <i>Translational Oncology</i> , 2021, 14, 100984.	1.7	9
4	Glioblastoma TCGA Mesenchymal and IGS 23 Tumors are Identifiable by IHC and have an Immune-phenotype Indicating a Potential Benefit from Immunotherapy. <i>Clinical Cancer Research</i> , 2020, 26, 6600-6609.	3.2	10
5	Phase Ia Study of Anti-NaPi2b Antibody <sup>+</sup> Drug Conjugate Lifestuzumab Vedotin DNIB0600A in Patients with Non <sup>+</sup> Small Cell Lung Cancer and Platinum-Resistant Ovarian Cancer. <i>Clinical Cancer Research</i> , 2020, 26, 364-372.	3.2	29
6	High Numbers of Circulating CD57 <sup>+</sup> NK Cells Associate with Resistance to HER2-Specific Therapeutic Antibodies in HER2 <sup>+</sup> Primary Breast Cancer. <i>Cancer Immunology Research</i> , 2019, 7, 1280-1292.	1.6	25
7	A phase Ib/II study of HER3-targeting lumretuzumab in combination with carboplatin and paclitaxel as first-line treatment in patients with advanced or metastatic squamous non-small cell lung cancer. <i>ESMO Open</i> , 2019, 4, e000532.	2.0	13
8	NK Cell Infiltrates and HLA Class I Expression in Primary HER2 <sup>+</sup> Breast Cancer Predict and Uncouple Pathological Response and Disease-free Survival. <i>Clinical Cancer Research</i> , 2019, 25, 1535-1545.	3.2	86
9	Phase Ib study evaluating safety and clinical activity of the anti-HER3 antibody lumretuzumab combined with the anti-HER2 antibody pertuzumab and paclitaxel in HER3-positive, HER2-low metastatic breast cancer. <i>Investigational New Drugs</i> , 2018, 36, 848-859.	1.2	55
10	First-in-Human Phase I Study of Single-agent Vanucizumab, A First-in-Class Bispecific Anti-Angiopoietin-2/Anti-VEGF-A Antibody, in Adult Patients with Advanced Solid Tumors. <i>Clinical Cancer Research</i> , 2018, 24, 1536-1545.	3.2	76
11	Phase Ib Study of Lumretuzumab Plus Cetuximab or Erlotinib in Solid Tumor Patients and Evaluation of HER3 and Heregulin as Potential Biomarkers of Clinical Activity. <i>Clinical Cancer Research</i> , 2017, 23, 5406-5415.	3.2	29
12	A Comparison of RNA-Seq Results from Paired Formalin-Fixed Paraffin-Embedded and Fresh-Frozen Glioblastoma Tissue Samples. <i>PLoS ONE</i> , 2017, 12, e0170632.	1.1	100
13	First-in-Human Phase I Study of Lumretuzumab, a Glycoengineered Humanized Anti-HER3 Monoclonal Antibody, in Patients with Metastatic or Advanced HER3-Positive Solid Tumors. <i>Clinical Cancer Research</i> , 2016, 22, 877-885.	3.2	59